U.S. In Vivo Cro Market Size & Outlook, 2024-2030

The in vivo cro market in the United States is expected to reach a projected revenue of US$ 3,003.9 million by 2030. A compound annual growth rate of 8.3% is expected of the United States in vivo cro market from 2025 to 2030.
Revenue, 2024 (US$M)
$1,866.8
Forecast, 2030 (US$M)
$3,003.9
CAGR, 2025 - 2030
8.3%
Report Coverage
U.S.

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

U.S. in vivo cro market, 2018-2030 (US$M)

U.S. in vivo cro market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

U.S. in vivo cro market highlights

  • The U.S. in vivo cro market generated a revenue of USD 1,726.4 million in 2023 and is expected to reach USD 3,003.9 million by 2030.
  • The U.S. market is expected to grow at a CAGR of 8.2% from 2024 to 2030.
  • In terms of segment, small molecule was the largest revenue generating modality type in 2023.
  • Large Molecule is the most lucrative modality type segment registering the fastest growth during the forecast period.


In vivo cro market data book summary

Market revenue in 2023USD 1,726.4 million
Market revenue in 2030USD 3,003.9 million
Growth rate8.2% (CAGR from 2023 to 2030)
Largest segmentSmall molecule
Fastest growing segmentLarge Molecule
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationSmall Molecule, Large Molecule
Key market players worldwideIQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group


Other key industry trends

  • In terms of revenue, U.S. accounted for 37.4% of the global in vivo cro market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In North America, U.S. in vivo cro market is projected to lead the regional market in terms of revenue in 2030.
  • U.S. is the fastest growing regional market in North America and is projected to reach USD 3,003.9 million by 2030.

Small molecule was the largest segment with a revenue share of 63.64% in 2024. Horizon Databook has segmented the U.S. in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.


Pharmaceutical and biotech companies across Europe and Asia are increasingly outsourcing in vivo activities to the U.S.-based CROs to enter the U.S. market. The U.S.-based CROs offer high-quality services, scientific expertise, and an increasing number of partnerships, making them an excellent choice for these companies. In addition, the patent expiry is another factor encouraging the adoption of U.S.-based CROs.

This, in turn, is expected to fuel the in vivo CRO market growth. However, stringent regulatory scenarios and cost containment pressure may pose challenges for the market in the U.S. Furthermore, the U.S. has a robust pharmaceutical and biotechnology industry that continuously focuses on drug discovery and development.

This emphasis has improved the demand for in vivo CRO services, as these organizations play a crucial role in conducting preclinical and clinical research. Several pharmaceutical companies have increasingly outsourced various aspects of their Research and Development (R&D) activities to cater to the growing demand, including preclinical testing.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

In Vivo CRO Market Companies

Name Profile # Employees HQ Website
SMO-Group View profile 101-250 Kiev, Kyyivs'ka Oblast', Ukraine, Europe https://www.smo-group.com/
Biocytogen View profile 1001-5000 Daxing, Beijing, China, Asia https://biocytogen.com
PsychoGenics View profile 101-250 Paramus, New Jersey, United States, North America http://psychogenics.com
GemPharmatech View profile 1001-5000 Nanjing, Jiangsu, China, Asia http://www.gempharmatech.com/
Janvier Labs View profile 251-500 Le Genest, Pays de la Loire, France, Europe https://janvier-labs.com
Taconic Biosciences View profile 501-1000 Hudson, New York, United States, North America http://www.taconic.com
JSR Corp View profile 7994 1-9-2 Higashi-Shimbashi, Shiodome Sumitomo Building, 22nd Floor, Minato-ku, Tokyo, Japan, 105-8640 http://www.jsr.co.jp
Evotec SE View profile 5055 Essener Bogen 7, Manfred Eigen Campus, Hamburg, Germany, 22419 https://www.evotec.com
PAREXEL View profile 10001+ Waltham, Massachusetts, United States, North America http://www.parexel.com
IQVIA Holdings Inc View profile 87000 2400 Ellis Road, Durham, NC, United States, 27703 https://www.iqvia.com
Icon PLC View profile 41150 South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 https://www.iconplc.com
Labcorp Holdings Inc View profile 67000 358 South Main Street, Burlington, NC, United States, 27215 https://www.labcorp.com
Charles River Laboratories International Inc View profile 21400 251 Ballardvale Street, Wilmington, MA, United States, 01887 https://www.criver.com

U.S. in vivo cro market size, by cell & gene therapy, 2018-2030 (US$M)

U.S. In Vivo CRO Market Outlook Share, 2024 & 2030 (US$M)

U.S. in vivo cro market size, by cell & gene therapy, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online